Phase III Result Favors Roche's Diabetes Drug Candidate Over Januvia

Per a Wall Street Journal, just right away -- a snippet, upon Januvia (sitagliptin), from a longer article (do go review it all, there):
. . . .Roche Holding AG said Wednesday an experimental once-weekly diagnosis under development works improved in treating a type of diabetes than Merck's Januvia, according to a clinical study.

The Basel-based drug company is comparing taspoglutide to Januvia as well as to a remedy in Phase-III studies upon Type 2 diabetes, as well as said a drug met primary endpoints as well as was well-tolerated by patients taking it. . . .
For its part, Merck has already released a statement reaffirming its idea in Januvia. This as well should infer interesting -- since a prior FDA notice upon pancreatitis risks -- associated with Januvia.